# GHK-Cu (Copper Peptide / Copper Tripeptide-1)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 2-3 (RCT data for topical; pilot RCT for injectable)
**Risk Profile:** LOW

---

## What Is This?

GHK-Cu is a naturally occurring copper-carrying peptide that your body produces less of as you age (dropping from 200 ng/mL at age 20 to 80 ng/mL by age 60). It's best known for skin rejuvenation — a 2024 RCT showed 28% average collagen increase with topical use. It modulates an impressive 31% of human genes, affecting wound healing, inflammation, and tissue repair. The topical form has decades of safe use in cosmetics; injectable use is less studied but growing in popularity.

---

## Categories

`Skin & Collagen` · `Tissue Repair` · `Longevity`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| INCI | International Nomenclature of Cosmetic Ingredients — standard naming for cosmetics |
| RCT | Randomised Controlled Trial — gold-standard research design |
| TGF-beta | Transforming Growth Factor-beta — promotes wound healing and collagen production |
| Angiogenesis | Formation of new blood vessels |
| IL-6, TNF-alpha | Inflammatory cytokines (signalling molecules) |
| Wilson's Disease | Genetic condition causing dangerous copper accumulation |
| GRAS | Generally Recognised As Safe — FDA designation |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Sequence | Gly-His-Lys + Cu2+ |
| Molecular Weight | 403.9 g/mol |
| INCI Name | Copper Tripeptide-1 |
| Natural Plasma Level (age 20) | ~200 ng/mL |
| Natural Plasma Level (age 60) | ~80 ng/mL |
| Half-life | 15-30 minutes |
| FDA Status | GRAS for cosmetics |

---

## Clinical Evidence

### The Topical Evidence Base

GHK-Cu enjoys something rare in the peptide world: actual randomised controlled trial data for its most common application. The 2024 Yuvan Research trial enrolled 21 women volunteers who applied topical GHK-Cu gel daily for three months. The results were striking — average collagen increase of 28%, with top quartile responders achieving 51% improvement. This wasn't an industry-funded promotional study but an IRB-approved, controlled trial.

Earlier comparison studies had already suggested GHK-Cu's potency. Twelve-week trials showed 70% improved collagen production with GHK-Cu versus 50% with vitamin C. Head-to-head comparisons with retinoic acid — long considered the gold standard for topical anti-aging — demonstrated superior collagen stimulation with GHK-Cu, and without retinoic acid's irritation profile.

### The Injectable Evidence Gap

Injectable GHK-Cu exists in a different evidence tier. Research protocols have used approximately 2.2 mcg/kg doses (roughly 140 mcg/injection in humans) over 10-day treatment periods. These provide proof of concept but fall short of robust efficacy data. The bodybuilding and clinic protocols employing 1-2mg daily doses are empirical extrapolations, not trial-validated regimens.

### Mechanistic Understanding

Where GHK-Cu stands out is mechanistic depth. Gene expression studies reveal the peptide modulates 31.2% of human genes — a scope that makes single-pathway explanations inadequate. It upregulates collagen types I and III directly. It activates the TGF-beta pathway, promoting wound healing and tissue remodelling. It stimulates angiogenesis, delivering nutrients to repair sites. And it dampens inflammation by reducing IL-6 and TNF-alpha, creating conditions where healing can proceed without inflammatory interference.

This broad gene modulation explains why GHK-Cu effects extend beyond skin: emerging animal data suggests benefits for lung tissue, liver fibrosis, and neuroprotection.

---

## Age-Related Decline

The rationale for GHK-Cu supplementation rests partly on its natural decline with age. Plasma levels drop from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60 — a 60% reduction. By age 80, levels fall to roughly 25% of youthful concentrations.

| Age | Plasma GHK-Cu | % of Peak |
|-----|---------------|-----------|
| 20 | 200 ng/mL | 100% |
| 40 | 140 ng/mL | 70% |
| 60 | 80 ng/mL | 40% |
| 80 | ~50 ng/mL | 25% |

This decline correlates with reduced wound healing capacity, decreased collagen production, visible skin aging, and slower overall recovery. Whether restoring youthful levels reverses these changes is the hypothesis driving GHK-Cu use; the topical evidence suggests it may, at least for skin.

---

## Safety Profile

GHK-Cu's safety record is among the strongest in the peptide space, largely because topical formulations have been used in cosmetics for decades without significant adverse effects. The copper component — which gives the peptide its blue-green colour — is well-regulated by the body's copper homeostasis systems at normal doses.

| Consideration | Details |
|---------------|---------|
| Wilson's Disease | Contraindicated (copper accumulation) |
| Injection site | Temporary redness, mild swelling |
| Copper toxicity | Only at extreme doses; body regulates well |
| Long-term injectable | Monitor copper levels if high-dose |

---

## Use Cases by Goal

### Skin Rejuvenation / Anti-Aging (Topical)

This is GHK-Cu's best-supported application, backed by RCT evidence. The rationale is straightforward: restore declining GHK-Cu levels to support collagen synthesis that naturally diminishes with age.

**Protocol:** Topical 0.1-1% cream/serum, 1-2x daily
**Duration:** 8-12 weeks minimum
**Timing:** After cleansing, before moisturiser; works best with penetration enhancers
**Evidence:** 2024 RCT showed 28% collagen increase, top responders 51%

### Wound Healing / Post-Procedure Recovery

GHK-Cu accelerates re-epithelialisation and reduces scarring through its TGF-beta and angiogenic effects. Both topical and systemic applications have been used.

**Protocol:** Topical application to affected area 2x daily; injectable 1-2mg daily for systemic
**Duration:** Until healed

### Hair Growth Support

GHK-Cu stimulates hair follicle cells and increases follicle size, effects consistent with its broader tissue regeneration profile.

**Protocol:** Topical to scalp daily or injectable 1-2mg daily
**Duration:** 3-6 months minimum

### Systemic Anti-Aging (Injectable)

The breadth of GHK-Cu's gene modulation — affecting nearly a third of human genes — suggests systemic effects beyond skin. Users pursue injectable administration for whole-body regenerative benefits, though this application lacks RCT validation.

**Protocol:** 1-2mg SC daily
**Duration:** 8-12 weeks
**Timing:** Any time of day
**Caution:** ~10% experience significant injection site reactions

### Lung/COPD Support (Experimental)

Animal data suggests GHK-Cu supports lung tissue repair. Human data is emerging but currently preclinical only.

**Protocol:** 1-2mg SC daily
**Duration:** 8-12 weeks
**Evidence Level:** Preclinical only

### With BPC-157 or TB-500 (Healing Stack)

Combining GHK-Cu's collagen synthesis effects with BPC-157's NO system modulation or TB-500's stem cell mobilisation addresses tissue repair through complementary mechanisms.

**Protocol:** GHK-Cu 1-2mg + BPC-157 250mcg daily
**Duration:** 4-8 weeks

---

## Injection Site Considerations

Injectable GHK-Cu produces noticeable reactions in a minority of users. Approximately 90% tolerate it well, reporting only mild, transient redness. However, roughly 10% experience significant reactions: temporary heat and redness (common, mild), blue discoloration lasting 2-3 days from the copper ion, golf ball-sized knots lasting a week (rare but documented), and injection site pain.

**If significant reactions occur:** Switch to topical route exclusively. The evidence base for topical is stronger anyway.

---

## Dosing Summary

### Trial-Validated (Topical Only)

| Study | Formulation | Duration |
|-------|-------------|----------|
| Yuvan 2024 RCT | 0.1-1% gel | 3 months daily |
| Comparison studies | 0.1-1% cream/serum | 8-12 weeks |

**Topical has the only RCT evidence.**

### Empirical Injectable Protocols (NOT Trial-Validated)

| Protocol | Dose | Frequency |
|----------|------|-----------|
| Starting | 1mg | Daily SC |
| Standard | 1-2mg | Daily SC |
| Loading | 2-3mg | Daily x 4 weeks, then maintain |

**Note:** These injectable doses are from bodybuilding/clinic use, not controlled trials.

### Monitoring (For Injectable Use)

| Test | Baseline | Ongoing | Rationale |
|------|----------|---------|-----------|
| Serum copper | Yes | Monthly if high-dose | Accumulation risk |
| Ceruloplasmin | Yes | - | Wilson's disease screening |
| Liver function | Yes | As indicated | Copper hepatotoxicity |
| PSA (men >40) | Yes | Every 6 months | Prostate surveillance |
| CEA | Yes | Every 6 months | Colorectal marker |
| CA-125 (women) | Yes | Every 6 months | Ovarian surveillance |

**Stop injectable if serum copper rises significantly above normal range.**

### Tumour Marker Cessation Rule

**Any elevation in PSA, CEA, or CA-125:** Immediate cessation of ALL growth factors (GH peptides, BPC-157, TB-500, GHK-Cu, Dihexa)

GHK-Cu promotes angiogenesis through the VEGF pathway — the same pathway tumours exploit for growth and metastasis. While GHK-Cu's cancer risk is lower than TB-500's documented oncogenic activity, the angiogenic mechanism warrants monitoring.

### Administration Notes

- Subcutaneous injection (abdomen, thigh)
- Blue-green colour is normal (copper ion)
- Can combine with other peptides in same injection
- Topical has strongest evidence base

---

## Effects Timeline

| Week | Observation |
|------|-------------|
| 1-2 | Injection site skin improvement |
| 3-4 | General skin glow |
| 6-8 | Wound healing improvement |
| 8-12 | Visible collagen effects |
| 12+ | Continued improvement |

Effects are gradual and cumulative. GHK-Cu works by modifying gene expression and stimulating biological processes that take time to manifest visibly.

---

## Applications

**Established (Strong Evidence):**
- Skin rejuvenation
- Wound healing
- Collagen synthesis

**Emerging (Animal/Mechanistic Data):**
- COPD (lung tissue)
- Liver fibrosis
- Neuroprotection
- Cartilage support

---

## Synergies

### With BPC-157

Different healing pathways — BPC-157's NO system modulation complements GHK-Cu's collagen synthesis and gene modulation.

### With TB-500

Systemic stem cell effects (TB-500) plus collagen/tissue quality (GHK-Cu) addresses both cellular recruitment and tissue building material.

### With Vitamin C

Vitamin C serves as a collagen synthesis cofactor. Combining it with GHK-Cu provides both the stimulus and the substrate for collagen production.

### With Retinoids

Complementary gene targets may enhance anti-aging effects, though both affect similar pathways.

---

## Limitations

1. Most robust data is for **topical application**
2. Injectable RCT is promising but limited (n=21)
3. Long-term injectable safety data lacking
4. Systemic effects beyond skin less studied

---

## References

1. Pickart L, Margolina A. Regenerative and Protective Actions of GHK-Cu. Int J Mol Sci. 2018. PMC6073405
2. Badenhorst T, et al. Injectable GHK-Cu for Skin Rejuvenation: RCT. J Cosmet Dermatol. 2024.
3. Kang YA, et al. GHK-Cu increases integrin expression by keratinocytes. Arch Dermatol Res. 2009.
4. Siméon A, et al. GHK-Cu effects on glycosaminoglycans in wounds. J Invest Dermatol. 2000.
5. EurekAlert press release on Yuvan Research clinical trial. 2024.
